SUMMARY
As participant to the virtual 2020 ASH meeting, we missed the bay of San Diego and the interesting face-to-face discussions with our friends and colleagues but we got some answers that were very useful for our Multiple Myeloma (MM) practice in Belgium. There were highlights on the efficacy of high dose Melphalan (HDM) and autologous stem cell transplantation (ASCT), the MRD negativity as a surrogate marker of progression free survival (PFS) and updates on recent quadruplets-based studies.
(BELG J HEMATOL 2021;12(1):8-13)
